AXL in cancer: a modulator of drug resistance and therapeutic target

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yaoxiang, Zang, Hongjing, Wen, Qiuyuan, Fan, Songqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273696/
https://www.ncbi.nlm.nih.gov/pubmed/37328828
http://dx.doi.org/10.1186/s13046-023-02726-w
_version_ 1785059698359140352
author Tang, Yaoxiang
Zang, Hongjing
Wen, Qiuyuan
Fan, Songqing
author_facet Tang, Yaoxiang
Zang, Hongjing
Wen, Qiuyuan
Fan, Songqing
author_sort Tang, Yaoxiang
collection PubMed
description AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.
format Online
Article
Text
id pubmed-10273696
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102736962023-06-17 AXL in cancer: a modulator of drug resistance and therapeutic target Tang, Yaoxiang Zang, Hongjing Wen, Qiuyuan Fan, Songqing J Exp Clin Cancer Res Review AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment. BioMed Central 2023-06-16 /pmc/articles/PMC10273696/ /pubmed/37328828 http://dx.doi.org/10.1186/s13046-023-02726-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Tang, Yaoxiang
Zang, Hongjing
Wen, Qiuyuan
Fan, Songqing
AXL in cancer: a modulator of drug resistance and therapeutic target
title AXL in cancer: a modulator of drug resistance and therapeutic target
title_full AXL in cancer: a modulator of drug resistance and therapeutic target
title_fullStr AXL in cancer: a modulator of drug resistance and therapeutic target
title_full_unstemmed AXL in cancer: a modulator of drug resistance and therapeutic target
title_short AXL in cancer: a modulator of drug resistance and therapeutic target
title_sort axl in cancer: a modulator of drug resistance and therapeutic target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273696/
https://www.ncbi.nlm.nih.gov/pubmed/37328828
http://dx.doi.org/10.1186/s13046-023-02726-w
work_keys_str_mv AT tangyaoxiang axlincanceramodulatorofdrugresistanceandtherapeutictarget
AT zanghongjing axlincanceramodulatorofdrugresistanceandtherapeutictarget
AT wenqiuyuan axlincanceramodulatorofdrugresistanceandtherapeutictarget
AT fansongqing axlincanceramodulatorofdrugresistanceandtherapeutictarget

Ejemplares similares